Eyepoint Pharmaceuticals (NASDAQ:EYPT) Given New $30.00 Price Target at HC Wainwright

Eyepoint Pharmaceuticals (NASDAQ:EYPT) had its price objective lifted by HC Wainwright from $23.00 to $30.00 in a research note issued to investors on Thursday,Benzinga reports. They currently have a buy rating on the stock.

Other equities analysts have also recently issued reports about the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Eyepoint Pharmaceuticals in a report on Thursday, January 22nd. Cantor Fitzgerald upgraded Eyepoint Pharmaceuticals to a “strong-buy” rating in a research report on Tuesday, November 25th. Chardan Capital upped their target price on Eyepoint Pharmaceuticals from $27.00 to $29.00 and gave the stock a “buy” rating in a research note on Wednesday. TD Cowen raised shares of Eyepoint Pharmaceuticals to a “strong-buy” rating in a research note on Friday, December 19th. Finally, Royal Bank Of Canada boosted their price objective on shares of Eyepoint Pharmaceuticals from $28.00 to $39.00 and gave the stock an “outperform” rating in a report on Thursday, November 6th. Two equities research analysts have rated the stock with a Strong Buy rating, four have given a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Buy” and an average target price of $31.50.

Eyepoint Pharmaceuticals Price Performance

Shares of NASDAQ:EYPT opened at $15.76 on Thursday. The company’s fifty day moving average price is $15.71 and its 200-day moving average price is $14.32. The firm has a market capitalization of $1.30 billion, a price-to-earnings ratio of -4.99 and a beta of 1.72. Eyepoint Pharmaceuticals has a one year low of $3.91 and a one year high of $19.11.

Eyepoint Pharmaceuticals (NASDAQ:EYPT) last announced its earnings results on Wednesday, March 4th. The company reported ($0.81) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.78) by ($0.03). The company had revenue of $0.62 million during the quarter, compared to analysts’ expectations of $1.01 million. Eyepoint Pharmaceuticals had a negative return on equity of 93.46% and a negative net margin of 739.39%. As a group, equities research analysts expect that Eyepoint Pharmaceuticals will post -2.13 EPS for the current year.

Insider Buying and Selling

In other Eyepoint Pharmaceuticals news, insider Ramiro Ribeiro sold 42,544 shares of the business’s stock in a transaction that occurred on Monday, January 5th. The stock was sold at an average price of $17.10, for a total value of $727,502.40. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 4.46% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in the company. Nisa Investment Advisors LLC raised its holdings in Eyepoint Pharmaceuticals by 1,636.5% during the 2nd quarter. Nisa Investment Advisors LLC now owns 2,900 shares of the company’s stock valued at $27,000 after buying an additional 2,733 shares during the last quarter. Franklin Resources Inc. increased its position in shares of Eyepoint Pharmaceuticals by 3.6% in the second quarter. Franklin Resources Inc. now owns 4,301,123 shares of the company’s stock valued at $40,474,000 after acquiring an additional 151,262 shares during the period. Rhumbline Advisers raised its stake in shares of Eyepoint Pharmaceuticals by 11.0% during the second quarter. Rhumbline Advisers now owns 96,280 shares of the company’s stock valued at $906,000 after acquiring an additional 9,548 shares during the last quarter. American Century Companies Inc. raised its stake in shares of Eyepoint Pharmaceuticals by 57.8% during the second quarter. American Century Companies Inc. now owns 67,612 shares of the company’s stock valued at $636,000 after acquiring an additional 24,752 shares during the last quarter. Finally, XTX Topco Ltd boosted its holdings in shares of Eyepoint Pharmaceuticals by 215.4% during the second quarter. XTX Topco Ltd now owns 137,950 shares of the company’s stock worth $1,298,000 after purchasing an additional 94,210 shares during the period. 99.41% of the stock is owned by hedge funds and other institutional investors.

Eyepoint Pharmaceuticals News Roundup

Here are the key news stories impacting Eyepoint Pharmaceuticals this week:

• Positive Sentiment: Analysts raised targets and reiterated buys—HC Wainwright boosted its price target to $30 (buy) and Chardan raised its target to $29 (buy), both implying large upside versus the current share price. Benzinga TickerReport
• Positive Sentiment: Pipeline and commercial-readiness updates: company says both pivotal Phase 3 trials for DURAVYU in wet AMD are on track for mid‑2026 readouts, patients are being dosed in DME trials, a chief commercial officer was appointed, and EyePoint reported >$300M in cash and investments (runway into Q4 2027)—all support a credible launch pathway if trials succeed. Press Release
• Neutral Sentiment: Company set a clear mid‑2026 topline target for DURAVYU readouts, which clarifies timing risk but keeps outcome risk high until data are reported. Article
• Neutral Sentiment: Reported short-interest data for March appear anomalous (showing 0 shares and NaN changes), so there’s no clear short‑squeeze signal from the available short‑interest report; treat that item as unreliable until clarified.
• Negative Sentiment: Quarterly results disappointed on EPS and revenue—Q4 EPS was a ($0.81) loss versus consensus ($0.78) and reported revenue was $0.62M (below some analyst expectations). The company also reported wide negative margins and negative ROE, highlighting near‑term profitability challenges that can pressure the stock. Earnings Transcript Press Release PDF
• Negative Sentiment: Investor caution: recent commentary (Seeking Alpha) warns that a pre‑readout runup may be masking commercial risks and execution hurdles—this kind of narrative can prompt profit‑taking ahead of pivotal data. Seeking Alpha

Eyepoint Pharmaceuticals Company Profile

Eyepoint Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapies for the treatment of ocular diseases. The company’s proprietary platform centers on sustained-release formulations designed to improve drug delivery to the posterior segment of the eye, addressing conditions that often require repeated intravitreal injections or intensive topical regimens. Eyepoint’s commercial strategy combines in-house sales and marketing capabilities with targeted partnerships to bring its therapies to ophthalmologists and retina specialists across the United States.

Eyepoint’s lead products include YUTIQ, a fluocinolone acetonide intravitreal implant indicated for the prevention of relapse in non-infectious uveitis affecting the posterior segment of the eye, and DEXYCU, a dexamethasone intraocular suspension approved for postoperative inflammation following ocular surgery.